July 10, 2018
Did you know that one area that the Leukemia & Lymphoma Society (LLS) is heavily involved in is the pioneering research in immunotherapy, specifically in the area of vaccines. One of the visionary minds in this field is Dr. Ron Levy from Stanford University.
With support from LLS, Dr. Levy developed a vaccine that involves injecting two immune-boosting agents directly into solid tumors. Lab tests showed that the vaccine completely eradicated cancer cells in mice.
Now, a clinical trial is testing the remarkable approach among patients with lymphoma. “LLS is dedicated to solving blood cancers and so am I. We will work together to get this done,” says Dr. Levy. The experimental vaccine also holds promise for breast, colon and melanoma cancer.
Dr. Levy is not a newcomer to revolutionary discoveries. Known as the “antibody hero,” Dr. Levy embarked on a decades-long quest to uncover a treatment approach that would use the body’s immune system to develop antibodies against invading tumor cells.
His foundational work resulted in the FDA-approval of the first monoclonal antibody to treat cancer, rituximab (brand name: Rituxan), in 1997. Rituximab is now used as a standard therapy to treat many lymphomas and is also approved to treat rheumatoid arthritis.
Revolutionary treatment approaches, originally discovered through blood cancer research, are being tested in clinical trials for other cancers and diseases. OHC is proud to be a supporter of LLS and their work to cure cancer. For information on how you can support LLS, please visit lls.org.Comments (0)